amunix

Amunix is an industry leader in the discovery and development of long-acting protein- and peptide therapeutics.

Amunix is an industry leader in the discovery and development of long-acting protein- and peptide therapeutics. Amunix’ pipeline products are based on its proprietary XTEN half-life extension, XDC drug-conjugate delivery and ProTIA pro-drug, bispecific T cell engager platform technologies. Amunix has ongoing collaborations with biopharma corporations harnessing these delivery technologies over a wide range of therapeutic areas, delivering improved pharmaceutical safety, efficacy and dosing.